Kết quả điều trị u lympho không Hodgkin lan tỏa tế bào B lớn biểu hiện tại vú=Treatment outcomes of patients with breast diffuse large B cell non

Kết quả điều trị u lympho không Hodgkin lan tỏa tế bào B lớn biểu hiện tại vú=Treatment outcomes of patients with breast diffuse large B cell non – Hodgkin lymphoma

0 Người đánh giá. Xếp hạng trung bình 0

Tác giả: Huyền Nga Đỗ, Thị Thanh Hà Lại, Thị Thu Hường Nguyễn

Ngôn ngữ: vie

Ký hiệu phân loại:

Thông tin xuất bản: Tạp chí Y học Việt Nam (Tổng hội Y học Việt Nam), 2024

Mô tả vật lý: tr.99-105

Bộ sưu tập: Metadata

ID: 478120

Thêm vào giỏ

Đánh giá kết quả điều trị u lympho không Hodgkin lan tỏa tế bào B lớn biểu hiện tại vú. Đối tượng và phương pháp: Nghiên cứu mô tả trên người bệnh u lympho tế bào B lớn lan tỏa điều trị tại Bệnh viện K từ 2019 đến tháng 6 năm 2024. Kết quả: Có tổng số 33 bệnh nhân tham gia nghiên cứu. Giai đoạn I, II chiếm đa số với 17/33 (51,5%) bệnh nhân
nguyên phát tại vú chiếm 18/33 (54,5%) bệnh nhân
100% điều trị hóa chất phác đồ RCHOP
20 (60,6%) bệnh nhân được điều trị hóa chất đơn thuần, 12 (36,4%) bệnh nhân được nhận hóa chất kèm theo xạ trị củng cố, 27 (81,8%) bệnh nhân có dự phòng thâm nhiễm thần kinh trung ương. Tỷ lệ đáp ứng hoàn toàn sau 6 chu kỳ RCHOP là 84,8% (28/33 bệnh nhân), sau kết thúc điều trị là 87,9% (29/33 bệnh nhân). Tại thời điểm theo dõi trung vị 28 tháng, trung vị PFS và OS chưa đạt được, tỷ lệ PFS và OS tại thời điểm 3 năm tương ứng 64,6% và 80,4%. Kết luận: U lympho không Hodgkin lan tỏa tế bào B lớn biểu hiện tại vú có tiên lượng tốt, vị trí tái phát thường gặp tại thần kinh trung ương và tái phát tại chỗ, do vậy cần cân nhắc dự phòng xâm lấn và xạ trị củng cố tại vú đối với giai đoạn sớm.To evaluate the treatment outcomes of patients with breast diffuse large Bcell non-Hodgkin lymphoma Subjects and methods: A descriptive study was conducted on patients with diffuse large Bcell lymphoma treated at Vietnam National Cancer Hospital from 2019 to June 2024. Results: 33 eligible patients were enrolled. Stage I, II accounted for the majority with 17/33 (51.5%) patients, primary breast disease accounted for 18/33 (54.5%) patients, 100% received chemotherapy with RCHOP regimen, 20 (60.6%) patients received chemotherapy alone, 12 (36.4%) patients received chemotherapy with consolidation radiotherapy. Central nervous system (CNS) prophylaxis was given to 27 (81.8%) patients. The complete response rate after 6 cycles of RCHOP was 84.8% (28/33 patients), and after the completion of treatment, this rate was 87.9% (29/33 patients). At a median follow-up of 28 months, the median progression-free survival (PFS) and overall survival (OS) were not reached, with 3- year PFS and OS rates of 64.6% and 80.4%, respectively. Conclusion: Breast diffuse large B-cell non- Hodgkin lymphoma has a good prognosis. Recurrent disease often occurs in the central nervous system, or locally. Thus, CNS prophylaxis and consolidative radiotherapy of the breast in the early stage should be considered.

1. Đọc trực tuyến

1. Đọc trực tuyến

Tạo bộ sưu tập với mã QR